RomânăFără categorie
First CAR T Therapy Approved for Solid Tumors (Gastric and Eso-Gastric Junction Cancer) — For Everyone’s Understanding
What happened, in short?
In June 2026 , a breakthrough treatment for stomach cancer was approved in China . It is the first time in the world that a special type of therapy — called CAR T — has worked and been officially approved for a solid cancer (i.e., a cancer that forms a tumor, not a blood cancer).
What is CAR T therapy? A simple explanation
Think of your immune system as your body’s defense army . T cells are specialized “soldiers” that attack threats — including cancer cells. The problem is, sometimes these soldiers don’t recognize cancer cells as a threat.
CAR T therapy means that doctors:
- Takes the patient’s T cells
- They genetically modify them in the lab so that they recognize and attack cancer cells
- them into the body , where the modified “soldiers” know exactly what to attack.
What is this treatment called and who does it help?
Treatment name: Satricabtagene autoleucel (abbreviated: satri-cel)
Who can receive it:
- Patients with advanced stomach or esophageal-gastric junction cancer
- Which have a special protein on cancer cells (called Claudin18.2)
- And who have already tried at least 2 previous treatments without success
What results did it show in clinical trials?
The researchers compared patients treated with satri-cel to those receiving standard treatments. The results were significant :
| With the satyr | Without village | |
| Median survival | ~9 months | ~4 months |
| Time to disease worsening | ~3 months | ~2 months |
💡 In other words: Patients treated with satri-cel lived, on average, more than twice as long as those who did not receive the treatment.
Is it safe? What side effects can occur?
Like any powerful treatment, satri-cel has side effects. The most common is cytokine release syndrome (CRS) — literally, an inflammatory reaction of the body, similar to an internal “storm.”
The good news: In most patients, this reaction was mild or moderate and could be managed by doctors. There were no treatment-related deaths in the main studies.
Why is it so important?
Until now, CAR T therapy only worked on blood cancers (leukemias, lymphomas). Solid cancers — stomach, lung, breast, colon, etc. — were much more difficult to treat with this method, because:
- The tumor has a physical “barrier” that is difficult to penetrate
- The environment around the tumor “blocks” immune soldiers
Satri-cel has found a way to overcome these obstacles , opening a huge door for future treatments against solid cancers.
What’s next?
- currently only approved in China.
- Researchers around the world are working on similar therapies for other types of cancer.
- There are dozens of clinical trials underway globally
🏁 In short: Satri-cel is a treatment that “trains” the patient’s own immune cells to attack stomach cancer. It is the first treatment of its kind approved for a solid cancer and represents a historic step in the fight against cancer, offering hope where other treatments no longer worked.
bibliography
- CARsgen Therapeutics Holdings Limited. CARsgen announces NMPA approval of satricabtagene autoleucel (satri-cel) for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. Press release. 2026 Jun.
- National Medical Products Administration. Official approval notice for satricabtagene autoleucel (satri-cel). 2026.
- Nature Biotechnology News. First CAR T-cell therapy approved for solid tumors. Nature Biotechnology. 2026.
- Cancer Discovery News. First CAR T-cell therapy approved for solid tumors. Cancer Discovery. 2026.
- Nature Medicine. Claudin18.2-specific CAR T cells for gastrointestinal cancers: a first-in-human phase 1 trial. Nature Medicine. 2022.
Dr. Onisim Florin Senior Medical Oncologist